Skip to main content
SpringerLink
Log in

Frontier of Development for Metallodrugs on the Basis of Metallomic Pharmacology and Medicinal Inorganic Chemistry

  • Chapter
  • First Online:
Metallomics

  • 1026 Accesses

Abstract

Biological trace metals (bio-metals) such as iron (Fe), zinc (Zn), copper (Cu), and manganese (Mn) are essential to life and health of humans, and the success of platinum (Pt) drugs in the cancer chemotherapy has rapidly grown interest in developing inorganic pharmaceutical agents (metallodrugs) in medicinal chemistry, that is, medicinal inorganic chemistry, using either biologically essential metals or other trace metals with pharmacological functions. Transition metal complexes with unique chemical structures may be useful alternatives to the drug available to address some of the incurable diseases. Over thousand years after ancient people practiced many types of inorganic compounds, modern development of metallopharmaceutics has been achieved by P. Ehrlich and his coworkers, who found arsenic-containing arsphenamine (As) and established the concept of chemotherapy in 1910. Since the year, a wide variety of metallodrugs have been developed by many researchers, and some of them are clinically used worldwide involving cisplatin (Pt), auranofin (Au), and polaprezinc (Zn). In this chapter, we emphasize that metal complexes are an expanding of interest in the research field of treatment of lifestyle diseases such as diabetes mellitus and several cancers. Especially, we would like to review the current state for the research of metal-based nonclinical medicines for treatment of cancer and diabetes mellitus.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Uchiyama S, Yamaguchi M (2003) Alteration in serum and bone component findings induced in streotozotocin-diabetic rats is restored by zinc acexamate. Int J Mol Med 12:949–954

    CAS  PubMed  Google Scholar 

  2. Bakale RP, Naik GN, Mangannavar CV, Muchchandi IS, Shcherbakov IN, Frampton C, Gudasi KB (2014) Mixed ligand complex via zinc(II)-mediated in situ oxidative heterocyclization of hydrochloride salt of 2-chlorobenzaldehyde hydralazine hydrazone as potential of antihypertensive agent. Eur J Med Chem 73:38–45

    Article  CAS  PubMed  Google Scholar 

  3. Koya D, King GL (1998) Protein kinase C activation and the development of diabetic complications. Diabetes 47(6):859–866

    Article  CAS  PubMed  Google Scholar 

  4. Ohashi K, Kihara S, Ouchi N, Kumada M, Fujita K, Hiuge A, Hibuse T, Ryo M, Nishizawa H, Maeda N, Maeda K, Shibata R, Walsh K, Funahashi T, Shimomura I (2006) Adiponectin replenishment ameliorates obesity-related hypertension. Hypertension 47:1108–1116

    Article  CAS  PubMed  Google Scholar 

  5. Yoshikawa Y, Ueda E, Kawabe K, Miyak H, Takino T, Sakurai H, Kojima Y (2002) Development of new insulinomimetic zinc(II) picolinate complexes with a Zn(N2O2) coordination mode: structure characterization, in vitro, and in vivo studies. J Biol Inorg Chem 7:68–73

    Article  CAS  PubMed  Google Scholar 

  6. Adams C, Grey N, Magrath I, Miller A, Torode J (2010) The world cancer declaration: is the world catching up? Lancet Oncol 11:1018–1020

    Article  PubMed  Google Scholar 

  7. Liu S, Yamauchi H (2006) Hinokitiol, a metal chelator derived from natural plants, suppresses cell growth and disrupts androgen receptor signaling in prostate carcinoma cell lines. Biochem Biophys Res Commun 351:26–32

    Article  CAS  PubMed  Google Scholar 

  8. Liu W, Gust R (2013) Metal N-heterocyclic carbene complexes as potential antitumor metallodrugs. Chem Soc Rev 42:755–773

    Article  CAS  PubMed  Google Scholar 

  9. Sharma AM, Chetty VT (2005) Obesity, hypertension and insulin resistance. Acta Diabetol 42(Suppl 1):S3–S8

    Article  CAS  PubMed  Google Scholar 

  10. Yoshikawa Y, Yasui H (2012) Zinc complexes developed as metallopharmaceutics for treating diabetes mellitus based on the bio-medicinal inorganic chemistry. Curr Top Med Chem 12(3):210–218

    Article  CAS  PubMed  Google Scholar 

  11. Barnard PJ, Baker MV, Berners-Price SJ, Skelton BW, White AH (2004) Dinuclear gold(I) complexes of bridging bidentate carbene ligands: synthesis, structure and spectroscopic characterisation. Dalton Trans 7(7):1038–1047

    Article  Google Scholar 

  12. Pantelića N, Stanojkovićb TP, Zmejkovskic BB, Sabod TJ, Kaluđerović GN (2015) In vitro anticancer activity of gold(III) complexes with some esters of (S, S)-ethylenediamine-N, N’-di-2-propanoic acid. Eur J Med Chem 90:766–774

    Article  Google Scholar 

  13. Atik OS, Uslu MM, Eksioglu F, Satana T (2006) Etiology of senile osteoporosis: a hypothesis. Clin Orthop Relat Res 443:25–27

    Article  PubMed  Google Scholar 

  14. Barnard PJ, Wedlock LE, Baker MV, Berners-Price SJ, Joyce DA, Skelton BW, Steer JH (2006) Luminescence studies of the intracellular distribution of a dinuclear gold(I) N-heterocyclic carbene complex. Angew Chem Int Ed Engl 45:5966–5970

    Article  CAS  PubMed  Google Scholar 

  15. Manrique C, Lastra G, Whaley-Connell A, Sowers JR (2005) Hypertension and the cardiometabolic syndrome. J Clin Hypertens 7(8):471–476

    Article  Google Scholar 

  16. Hoehn ST, Junker HD, Bunt RC, Turner CJ, Stubbe J (2001) Solution structure of Co(III)-bleomycin-OOH bound to a phosphoglycolate lesion containing oligonucleotide: implications for bleomycin-induced double-strand DNA cleavage. Biochemistry 40:5894–5905

    Article  CAS  PubMed  Google Scholar 

  17. Hie M, Tsukamoto I (2011) Administration of zinc inhibits osteoclastogenesis through the suppression of RANK expression in bone. Eur J Pharmacol 668:140–146

    Article  CAS  PubMed  Google Scholar 

  18. Tokudome Y, Otsuka M (2012) Possibility of alveolar bone promoting enhancement by using lipophilic and/or hydrophilic zinc related compounds in zinc-deficient osteoporosis rats. Biol Pharm Bull 35:1496–1501

    Article  CAS  PubMed  Google Scholar 

  19. Fujimoto S, Yasui H, Yoshikawa Y (2013) Development of a novel antidiabetic zinc complex with an organoselenium ligand at the lowest dosage in KK-Ay mice. J Inorg Biochem 121:10–15

    Article  CAS  PubMed  Google Scholar 

  20. Murakami H, Yasui H, Yoshikawa Y (2012) Pharmacological and pharmacokinetic studies of anti-diabetic tropolonato–Zn(II) complexes with Zn(S2O2) coordination mode. Chem Pharm Bull 60:1096–1104

    Article  CAS  PubMed  Google Scholar 

  21. Yanovski SZ, Yanovski JA (2014) Long-term drug treatment for obesity: a systematic and clinical review. JAMA 311(1):74–86

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Inzucchi SE, Zinman B, Wanner C, Ferrari R, Fitchett D, Hantel S, Espadero RM, Woerle HJ, Broedl UC, Johansen OE (2015) SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res 12(2):90–100

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Krishnamurthy D, Karver MR, Fiorillo E, Orrú V, Stanford SM, Bottini N, Barrios AM (2008) Gold(I)-mediated inhibition of protein tyrosine phosphatases: a detailed in vitro and cellular study. J Med Chem 51:4790–4795

    Article  CAS  PubMed  Google Scholar 

  24. Proetto MT, Liu W, Molchanov A, Sheldrick WS, Hagenbach A, Abram U, Gust R (2014) Synthesis, characterization, and in vitro antiproliferative activity of [salophene]platinum(II) complexes. Chem Med Chem 9:1176–1187

    Article  CAS  PubMed  Google Scholar 

  25. Shaw CF III (1999) Gold-based therapeutic agents. Chem Rev 99:2589–2600

    Article  CAS  Google Scholar 

  26. Ohly P, Dohle C, Abel J, Seissler J, Gleichmann H (2000) Zinc sulphate induces metallothionein in pancreatic islets of mice and protects against diabetes induced by multiple low doses of streptozotocin. Diabetologia 43:1020–1030

    Article  CAS  PubMed  Google Scholar 

  27. Naito Y, Yoshikawa Y, Yasui H (2011) Cellular mechanism of zinc–hinokitiol complexes in diabetes mellitus. Bull Chem Soc Jpn 84:298–305

    Article  CAS  Google Scholar 

  28. Yamaguchi M, Kishi S (1993) Prolonged administration of β-Alanyl-L-Histidinato Zinc prevents bone loss in Ovariectomized rats. Jpn J Pharmacol 63:203–207

    Article  CAS  PubMed  Google Scholar 

  29. Yoshikawa Y, Adachi Y, Yasui H, Hattori M, Sakurai H (2011) Oral administration of Bis(aspirinato)zinc(II) complex ameliorates hyperglycemia and metabolic syndrome-like disorders in spontaneously diabetic KK-Ay mice: structure-activity relationship on zinc-salicylate complexes. Chem Pharm Bull 59:972–977

    Article  CAS  PubMed  Google Scholar 

  30. Murphy SL, Xu J, Kochanek KD (2013) Deaths: final data for 2010. Natl Vital Stat Rep 61(4):1–117

    PubMed  Google Scholar 

  31. Margiotta N, Savino S, Gandin V, Marzano C, Natile G (2014) Monofunctional platinum(II) complexes with potent tumor cell growth inhibitory activity: the effect of a hydrogen-bond donor/acceptor N-heterocyclic ligand. Chem Med Chem 9:1161–1168

    Article  PubMed  Google Scholar 

  32. Rubbiani R, Salassa L, de Almeida A, Casini A, Ott I (2014) Cytotoxic gold(I) N-heterocyclic carbene complexes with phosphane ligands as potent enzyme inhibitors. Chem Med Chem 9:1205–1210

    Article  CAS  PubMed  Google Scholar 

  33. Sun RWY, Ma DL, Wong ELM, Che CM (2007) Some uses of transition metal complexes as anti-cancer and anti-HIV agents. Dalton Trans 21:4884–4892

    Google Scholar 

  34. Karieb S, Fox SW (2012) Zinc modifies the effect of phyto-oestrogens on osteoblast and osteoclast differentiation in vitro. Br J Nutr 108:1736–1745

    Article  CAS  PubMed  Google Scholar 

  35. Nakai M, Watanabe H, Fujisawa C, Kakegawa H, Satoh T, Takada J, Matsushita R, Sakurai H (1995) Mechanism on insulin-like action of vanadyl sulfate: studies on interaction between rat adipocytes and vanadium compounds. Biol Pharm Bull 18:719–725

    Article  CAS  PubMed  Google Scholar 

  36. Barret MC, Mahon MF, Molloy KC, Steed JW, Wright P (2001) Synthesis and structural characterization of tin(II) and zinc(II) derivatives of cyclic alpha-hydroxyketones, including the structures of Sn(maltol)2, Sn(tropolone)2, Zn(tropolone)2, and Zn(hinokitiol)2. Inorg Chem 40(17):4384–4388

    Article  CAS  PubMed  Google Scholar 

  37. Kanis JA, Johnell O, Oden A, Sembo I, Redlund-Johnell I, Dawson A, De Laet C, Jonsson B (2000) Long-term risk of osteoporotic fracture in Malmö. Osteoporos Int 11:669–674

    Article  CAS  PubMed  Google Scholar 

  38. Hu C, Li X, Wang W, Zhang R, Deng L (2014) Metal-N-heterocyclic carbene complexes as anti-tumor agents. Curr Med Chem 21:1220–1230

    Article  CAS  PubMed  Google Scholar 

  39. Tobia MH, Zdanowicz MM, Wingertzahn MA, McHeffey-Atkinson B, Slonim AE, Wapnir RA (1998) The role of dietary zinc in modifying the onset and severity of spontaneous diabetes in the BB Wistar Rat. Mol Genet Metab 63:205–213

    Article  CAS  PubMed  Google Scholar 

  40. Ball D, Blanchard J, Jacobson-Kram D, McClellan R, McGovern T, Norwood DL et al (2007) Development of safety qualification thresholds and their use in orally inhaled and nasal drug product evaluation. Toxicol Sci 97:226–236

    Article  CAS  PubMed  Google Scholar 

  41. Strianese M, Basile A, Mazzone A, Morello S, Turco MC, Pellecchia C (2013) Therapeutic potential of a pyridoxal-based vanadium(IV) complex showing selective cytotoxicity for cancer versus healthy cells. J Cell Physiol 228:2202–2209

    Article  CAS  PubMed  Google Scholar 

  42. Solanki V, Solanki M, Khubchandani A, Parmar V, Parmar U, Shah P (2015) Significance of serum levels of copper and zinc in hypertensive patients. Int J Res Med 4:137–139

    Google Scholar 

  43. Clough JD, Patel K, Riley GF, Rajkumar R, Conway PH, Bach PB (2015) Wide variation in payments for medicare beneficiary oncology services suggests room for practice-level improvement. Health Aff (Millwood) 34(4):601–608

    Article  Google Scholar 

  44. Tucker KL, Hannan MT, Kiel DP (2001) The acid-base hypothesis: diet and bone in the Framingham Osteoporosis study. Eur J Nutr 40:231–237

    Article  CAS  PubMed  Google Scholar 

  45. Yoshikawa Y, Ueda E, Miyake H, Sakurai H, Kojima Y (2001) Insulinomimetic bis(maltolato)zinc(II) complex: blood glucose normalizing effect in KK-Ay mice with type 2 diabetes mellitus. Biochem Biophys Res Commun 281:1190–1193

    Article  CAS  PubMed  Google Scholar 

  46. Duff B, Thangella VR, Creaven BS, Walsh M, Egan DA (2012) Anti-cancer activity and mutagenic potential of novel copper(II) quinolinone Schiff base complexes in hepatocarcinoma cells. Eur J Pharmacol 689:45–55

    Article  CAS  PubMed  Google Scholar 

  47. Begin-Heick N, Dalpe-Scott M, Rowe J, Heick HM (1985) Zinc supplementation attenuates insulin secretory activity in pancreatic islets of the ob/ob mouse. Diabetes 34:179–184

    Article  CAS  PubMed  Google Scholar 

  48. Gavin JR, Alberti KGMM, Davidson MB, DeFronzo RA, Drash A, Gabbe SG, Genuth S, Harris MI, Kahn R, Keen H, Knowler WC, Lebovitz H, Maclaren NK, Palmer JP, Raskin P, Rizza RA, Stem MP (1997) Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 20:1183–1197

    Article  Google Scholar 

  49. Birkmeyer NJ, Goodney PP, Stukel TA, Hillner BE, Birkmeyer JD (2005) Do cancer centers designated by the National Cancer Institute have better surgical outcomes? Cancer 103(3):435–441

    Article  PubMed  Google Scholar 

  50. Gao EJ, Liu C, Zhu MC, Lin HK, Wu Q, Liu L (2009) Current development of Pd(II) complexes as potential antitumor agents. Anticancer Agents Med Chem 9:356–368

    Article  CAS  PubMed  Google Scholar 

  51. Maschke M, Alborzinia H, Lieb M, Wölfl S, Metzler-Nolte N (2014) Structure-activity relationship of trifluoromethyl-containing metallocenes: electrochemistry, lipophilicity, cytotoxicity, and ROS production. Chem Med Chem 9:1188–1194

    Article  CAS  PubMed  Google Scholar 

  52. Mir LM, Tounekti O, Orlowski S (1996) Bleomycin: revival of an old drug. Gen Pharmacol 27:745–748

    Article  CAS  PubMed  Google Scholar 

  53. Qiu L, Lv G, Cao Y, Chen L, Yang H, Luo S, Zou M, Lin J (2015) Synthesis and biological evaluation of novel platinum complexes of imidazolyl-containing bisphosphonates as potential anticancer agents. J Biol Inorg Chem 20:1263–1275

    Article  CAS  PubMed  Google Scholar 

  54. Adachi Y, Yoshida J, Kodera Y, Kiss T, Jakusch T, Enyedy EA, Yoshikawa Y, Sakurai H (2006) Oral administration of a zinc complex improves type 2 diabetes and metabolic syndromes. Biochem Biophys Res Commun 351:165–170

    Article  CAS  PubMed  Google Scholar 

  55. Naso LG, Lezama L, Valcarcel M, Salado C, Villacé P, Kortazar D, Ferrer EG, Williams PA (2016) Bovine serum albumin binding, antioxidant and anticancer properties of an oxidovanadium(IV) complex with luteolin. J Inorg Biochem 157:80–93

    Article  CAS  PubMed  Google Scholar 

  56. Dokorou V, Primikiri A, Kovala-Demertzi D (2011) The triphenyltin(VI) complexes of NSAIDs and derivatives. Synthesis, crystal structure and antiproliferative activity. Potent anticancer agents. J Inorg Biochem 105:195–201

    Article  CAS  PubMed  Google Scholar 

  57. Ahera SB, Muskawara PN, Thenmozhib K, Bhagata PR (2014) Recent developments of metal N-heterocyclic carbenes as anticancer agents. Eur J Med Chem 81:408–419

    Article  Google Scholar 

  58. Trust TJ, Coombs RW (1973) Antibacterial activity of beta-thujaplicin. Can J Microbiol 19:1341–1346

    Article  CAS  PubMed  Google Scholar 

  59. Yoshikawa Y, Murakami H, Fujimoto S, Michigami K, Yasui H (2013) Zinc and lifestyle – related disease – with focus on diabetes mellitus and osteoporosis. Vitam Miner S6:002

    Article  Google Scholar 

  60. de Frémont P, Stevens ED, Eelman MD, Fogg DE, Nolan SP (2006) Gold(I) NHC complexes bearing biologically compatible moieties. Organometallics 25:5824–5828

    Article  Google Scholar 

  61. Kadowaki S, Munekane M, Kitamura Y, Hiromura M, Kamino S, Yoshikawa Y, Saji H, Enomoto S (2013) Development of new zinc dithiosemicarbazone complex for use as oral antidiabetic agent. Biol Trace Elem Res 154:111–119

    Article  CAS  PubMed  Google Scholar 

  62. Lewis JA, Tran BL, Puerta DT, Rumberger EM, Hendrickson DN, Cohen SM (2005) Synthesis, structure and spectroscopy of new thiopyrone and hydroxypyridinethione transition-metal complexes. Dalton Trans 7(15):2588–2596

    Article  Google Scholar 

  63. Yoshikawa Y, Kawabe K, Tadokoro M, Suzuki Y, Yanagihara N, Nakayama A, Sakurai H, Kojima Y (2002) New zinc(II) complexes with tetradentate amino acid derivatives: structure characterization, solution chemistry, and in vitro insulinomimetic activity. Bull Chem Soc Jpn 75:2423–2432

    Article  CAS  Google Scholar 

  64. Yamaguchi M, Uchiyama S, Ishiyama K, Hashimoto K (2006) Oral administration in combination with zinc enhances beta-cryptoxanthin-induced anabolic effects on bone components in the femoral tissues of rats in vivo. Biol Pharm Bull 29:371–374

    Article  CAS  PubMed  Google Scholar 

  65. Teyssot ML, Jarrousse AS, Manin M, Chevry A, Roche S, Norre F, Beaudoin C, Morel L, Boyer D, Mahiou R, Gautier A (2009) Metal-NHC complexes: a survey of anti-cancer properties. Dalton Trans 21:6894–6902

    Article  Google Scholar 

  66. Vujčić M, Lazić M, Milenković M, Sladić D, Radulović S, Filipović N, Anđelković K (2011) A comparative study of DNA binding and cell cycle phase perturbation by the dinuclear complex of Cd(II) with the condensation product of 2-acetylpyridine and malonic acid dihydrazide N′, N′ 2-bis[(1E)-1-(2-pyridyl)ethylidene]propanedihydrazide. J Biochem Mol Toxicol 25:175–182

    Article  PubMed  Google Scholar 

  67. Yamane M, Adachi Y, Yoshikawa Y, Sakurai H (2005) A new anti-diabetic Zn(II)-hinokitiol (β-Thujaplicin) complex with Zn(O4) coordination mode. Chem Lett 34:1694–1695

    Article  CAS  Google Scholar 

  68. Ray S, Mohan R, Singh JK, Samantaray MK, Shaikh MM, Panda D, Ghosh P (2007) Anticancer and antimicrobial metallopharmaceutical agents based on palladium, gold, and silver N-heterocyclic carbene complexes. J Am Chem Soc 129:15042–15053

    Article  CAS  PubMed  Google Scholar 

  69. Yoshikawa Y, Murayama A, Adachi Y, Sakurai H, Yasui H (2011) Challenge of studies on the development of new Zn complexes (Zn(opt)2) to treat diabetes mellitus. Metallomics 3:686–692

    Article  CAS  PubMed  Google Scholar 

  70. Body JJ, Bergmann P, Boonen S, Devogelaer JP, Gielen E, Goemaere S, Kaufman JM, Rozenberg S, Reginster JY (2012) Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medications. Osteoporos Int 23(Suppl 1):S1–S23

    Article  PubMed  PubMed Central  Google Scholar 

  71. Koide T, Yuguchi M, Kawakita M, Konno H (2002) Metal-assisted stabilization and probing of collagenous triple helices. J Am Chem Soc 124:9388–9389

    Article  CAS  PubMed  Google Scholar 

  72. Yoshikawa Y, Ueda E, Kawabe K, Miyake H, Sakurai H, Kojima Y (2000) New insulin-mimetic zinc(II) complexes; Bis-maltolato zinc(II) and bis-(2-hydroxypyridine-N-oxido) zinc(II) with Zn(O4) coordination mode. Chem Lett 29:874–875

    Article  Google Scholar 

  73. Yamaguchi M, Ozaki K, Suketa Y (1989) Alteration in bone metabolism with increasing age: effects of zinc and vitamin D3 in aged rats. J Pharmacobiodyn 12:67–73

    Article  CAS  PubMed  Google Scholar 

  74. Yan L, Tan J, Wan BC, Zhu LC (2014) Synthesis, characterization, and anti-cancer activity of emodin-Mn(II) metal complex. Chin J Nat Med 12:937–942

    Google Scholar 

  75. Song MK, Hwang IK, Rosenthal MJ, Harris DM, Yamaguchi DT, Yip I, Go VL (2003) Anti-hyperglycemic activity of zinc plus cyclo (his-pro) in genetically diabetic Goto-Kakizaki and aged rats. Exp Biol Med 228:1338–1345

    CAS  Google Scholar 

  76. Kaplan NM, Opie LH (2006) Controversies in hypertension. Lancet 367(9505):168–176

    Article  PubMed  Google Scholar 

  77. Qin XY, Yang LC, Le FL, Yu QQ, Sun DD, Liu YN, Liu J (2013) Structures and anti-cancer properties of two binuclear copper complexes. Dalton Trans 42:14681–14684

    Article  CAS  PubMed  Google Scholar 

  78. Underwood EJ (1977) In trace elements in human and animal nutrition, 4th edn. Academic, New York, p 545

    Google Scholar 

  79. Vijayaraghavan K, Iyyam Pillai S, Subramanian SP (2012) Design, synthesis and characterization of zinc-3 hydroxy flavone, a novel zinc metallo complex for the treatment of experimental diabetes in rats. Eur J Pharmacol 680:122–129

    Article  CAS  PubMed  Google Scholar 

  80. Sakurai H, Yoshikawa Y, Yasui H (2008) Current state for the development of metallopharmaceutics and anti-diabetic metal complexes. Chem Soc Rev 37:2383–2392

    Article  CAS  PubMed  Google Scholar 

  81. Yoshikawa Y, Adachi Y, Sakurai H (2007) A new type of orally active anti-diabetic Zn(II)-dithiocarbamate complex. Life Sci 80:759–766

    Article  CAS  PubMed  Google Scholar 

  82. Zhu K, Devine A, Prince RL (2009) The effects of high potassium consumption on bone mineral density in a prospective cohort study of elderly postmenopausal women. Osteoporos Int 20:335–340

    Article  CAS  PubMed  Google Scholar 

  83. Sakurai H, Kojima Y, Yoshikawa Y, Kawabe K, Yasui H (2002) Antidiabetic vanadium(IV) and zinc(II) complexes. Coord Chem Rev 226:187–198

    Article  CAS  Google Scholar 

  84. Rubbiani R, Kitanovic I, Alborzinia H, Can S, Kitanovic A, Onambele LA, Stefanopoulou M, Geldmacher Y, Sheldrick WS, Wolber G, Prokop A, Wölfl S, Ott I (2010) Benzimidazol-2-ylidene gold(I) complexes are thioredoxin reductase inhibitors with multiple antitumor properties. J Med Chem 53:8608–8618

    Article  CAS  PubMed  Google Scholar 

  85. Zec M, Srdic-Rajic T, Konic-Ristic A, Todorovic T, Andjelkovic K, Filipovic-Ljeskovic I, Radulovic S (2012) Anti-metastatic and anti-angiogenic properties of potential new anti-cancer drugs based on metal complexes of selenosemicarbazones. Anticancer Agents Med Chem 12:1071–1080

    Article  CAS  PubMed  Google Scholar 

  86. Smith RA, Manassaram-Baptiste D, Brooks D, Doroshenk M, Fedewa S, Saslow D, Brawley OW, Wender R (2015) Cancer screening in the United States, 2015: a review of current American cancer society guidelines and current issues in cancer screening. CA Cancer J Clin 65:30–54

    Article  PubMed  Google Scholar 

  87. Bray F, Jemal A, Grey N, Ferlay J, Forman D (2012) Global cancer transitions according to the Human Development Index (2008–2030): a population-based study. Lancet Oncol 13:790–801

    Article  PubMed  Google Scholar 

  88. Wanzlick HW, Schoenherr HJ (1968) Chemistry of nucleophilic carbenes. XIV. Direct synthesis of a mercury salt-carbene complex. Angew Chem Int Ed Engl 7:141–142

    Article  CAS  Google Scholar 

Download references

Acknowledgments

This review was financially supported in part by a grant from the Ministry of Education, Culture, Sports, and Technology of Japan (MEXT) Supported Program for the Strategic Research Foundation at Private Universities, 2012–2016 (S1201008).

Author information

Authors and Affiliations

  1. Department of Analytical and Bioinorganic Chemistry, Division of Analytical and Physical Sciences, Kyoto Pharmaceutical University, Kyoto, Japan

    Hiroyuki Yasui

  2. Department of Health, Sports and Nutrition, Faculty of Health and Welfare, Kobe Women’s University, Hyōgo, Japan

    Yutaka Yoshikawa

Authors
  1. Hiroyuki Yasui
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yutaka Yoshikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hiroyuki Yasui .

Editor information

Editors and Affiliations

  1. Graduate School of Pharmaceutical Science, Chiba University, Chiba, Japan

    Yasumitsu Ogra

  2. Graduate School of Science, The University of Tokyo, Tokyo, Japan

    Takafumi Hirata

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer Japan KK

About this chapter

Cite this chapter

Yasui, H., Yoshikawa, Y. (2017). Frontier of Development for Metallodrugs on the Basis of Metallomic Pharmacology and Medicinal Inorganic Chemistry. In: Ogra, Y., Hirata, T. (eds) Metallomics. Springer, Tokyo. https://doi.org/10.1007/978-4-431-56463-8_16

Download citation

Publish with us

Policies and ethics

Search

Navigation